Get the Stockscreener App
22.70
0.82%
0.14
Forte Biosciences Inc stock is traded at $22.70, with a volume of 3,159.
It is up +0.82% in the last 24 hours and up +14.12% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$22.56
Open:
$22.61
24h Volume:
3,159
Relative Volume:
0.03
Market Cap:
$280.85M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-21.83
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-13.42%
1M Performance:
+14.12%
6M Performance:
+66.51%
1Y Performance:
+0.64%
1-Day Range:
$22.01
$22.75
1-Week Range:
$21.86
$27.65
52-Week Range:
$4.90
$31.27
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
22.42 | 282.61M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Will Avax Apparels and Ornaments Limited Bounce From 52 Week LowPortfolio Risk Assessment & Interactive Learning for Better Returns - earlytimes.in
Forte Biosciences Inc Stock Analysis and ForecastVolatility Trading Techniques & Set Up Real-Time Alerts – It’s Free - earlytimes.in
What drives Forte Biosciences Inc stock priceMean Reversion Trades & Receive Monthly Expert Trading Blueprints - earlytimes.in
Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock - Yahoo Finance
Institutional investors may adopt severe steps after Forte Biosciences, Inc.'s (NASDAQ:FBRX) latest 15% drop adds to a year losses - simplywall.st
Insider Buying: Antony Riley Acquires Shares of Forte Biosciences Inc (FBRX) - GuruFocus
Trading Bots Trigger Alerts on Shri Venkatesh Refineries Limited ActivityHigh Frequency Trading Trends & Fast Profit Trading Ideas - bollywoodhelpline.com
Indo Tech Transformers Limited (INDOTECH) Stock RalliesStock Liquidity Analysis & Discover Stocks Experts Are Watching - bollywoodhelpline.com
Dr. Lal PathLabs Limited (LALPATHLAB) Expands into New MarketRisk-Reward Ratio Analysis & Fast Profit Capital Growth - bollywoodhelpline.com
Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Shorts Report: Will Forte Biosciences Inc stock return to pre crisis levelsJuly 2025 Update & Consistent Profit Trade Alerts - moha.gov.vn
(FBRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Gaining experience for doing equity researchDividend Yield Trends & Free Fastest Return On Investment - bollywoodhelpline.com
Rate Hike: Is Forte Biosciences Inc stock dividend yield sustainable2025 Pullback Review & Weekly Watchlist of Top Performers - moha.gov.vn
Stock Traders Buy Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Bluefield Daily Telegraph
New Forte Biosciences hire receives options for 75,000 shares - Stock Titan
Dental EconomicsForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - FinancialContent
Gainers Report: Can Cytosorbents Corporation stock deliver sustainable ROEJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Why analysts upgrade Forte Biosciences Inc. stock2025 Top Gainers & Expert Curated Trade Ideas - Улправда
Ester Industries Limited Recovers — But Is It SustainableGap Fill Strategies & Low Risk Capital Growth - Bollywood Helpline
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Dow Update: Why Dune Acquisition Corporation Equity Warrant stock remains on buy listsPortfolio Profit Report & Low Risk Entry Point Guides - Улправда
Will Forte Biosciences Inc. stock outperform international peersTrade Risk Report & AI Enhanced Execution Alerts - DonanımHaber
Forte Biosciences initiated with an Outperform at Evercore ISI - MSN
Is Forte Biosciences Positioned For More Gains Ahead Of 2026 Clinical Readouts? - RTTNews
Swing Trade: Will Forte Biosciences Inc 37T stock outperform value peers2025 Retail Activity & Growth Focused Investment Plans - moha.gov.vn
Forte Biosciences Earnings Notes - Trefis
Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year - Yahoo Finance
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX - MarketBeat
Stock Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Forte Biosciences (FBRX) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit Forte Biosciences Inc. (37T) stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - Newser
Recent Research Analysts’ Ratings Changes for Forte Biosciences (FBRX) - Defense World
What analyst consensus implies for Forte Biosciences Inc. (37T) stockWatch List & Trade Opportunity Analysis Reports - Newser
Is Forte Biosciences Inc. stock a top pick in earnings seasonJuly 2025 Update & Trade Opportunity Analysis - Newser
How forex fluctuations impact Forte Biosciences Inc. (37T) stockTrade Ideas & Weekly Hot Stock Watchlists - Newser
Is Forte Biosciences Inc. stock attractive for passive investors2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
18,856 Shares in Forte Biosciences, Inc. $FBRX Purchased by Envestnet Asset Management Inc. - MarketBeat
Forte Biosciences, Inc. (FBRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at Evercore ISI - MarketBeat
Forte Biosciences (NASDAQ:FBRX) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - MarketBeat
Analysts Set Forte Biosciences, Inc. (NASDAQ:FBRX) PT at $67.00 - Defense World
Why Forte Biosciences Inc. stock could benefit from AI revolution2025 Year in Review & AI Enhanced Market Trend Forecasts - BỘ NỘI VỤ
How does Forte Biosciences Inc (FBRX) change from a tortoise to a hare? - Setenews
Forte Biosciences, Inc. (NASDAQ:FBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):